Foghorn Therapeutics Inc.
FHTX
$4.54
-$0.045-0.98%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -33.83% | -21.66% | 61.95% | 64.41% | 77.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.83% | -21.66% | 61.95% | 64.41% | 77.63% |
| Cost of Revenue | -13.46% | 117.91% | 54.13% | 18.10% | 28.43% |
| Gross Profit | 6.60% | -283.82% | -51.45% | -7.54% | -17.48% |
| SG&A Expenses | -12.40% | -12.60% | -7.62% | -2.27% | 5.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.50% | -13.38% | -11.60% | -4.60% | 4.18% |
| Operating Income | 7.06% | 11.02% | 24.34% | 16.20% | 7.88% |
| Income Before Tax | 8.05% | 11.62% | 25.99% | 20.20% | 13.48% |
| Income Tax Expenses | -- | -11.34% | 81.36% | 554.64% | -- |
| Earnings from Continuing Operations | 11.99% | 11.61% | 24.59% | 17.34% | 9.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.99% | 11.61% | 24.59% | 17.34% | 9.60% |
| EBIT | 7.06% | 11.02% | 24.34% | 16.20% | 7.88% |
| EBITDA | 6.98% | 11.15% | 24.95% | 16.70% | 8.22% |
| EPS Basic | 29.65% | 22.51% | 29.03% | 18.16% | 10.37% |
| Normalized Basic EPS | 28.57% | 24.67% | 32.18% | 21.00% | 14.21% |
| EPS Diluted | 29.65% | 22.51% | 29.03% | 18.16% | 10.37% |
| Normalized Diluted EPS | 28.57% | 24.67% | 32.18% | 21.00% | 14.21% |
| Average Basic Shares Outstanding | 30.73% | 18.74% | 6.67% | 1.03% | 0.92% |
| Average Diluted Shares Outstanding | 30.73% | 18.74% | 6.67% | 1.03% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
